On January 6, 2026 AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, reported it will attend the 44th Annual J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, CA, and host meetings showcasing the Company’s recent accomplishments and sharing strategic plans moving forward. The Company’s Chairman and CEO, Tony (Bizuo) Liu, has also been invited as a panel speaker at the Conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Session:

Emerging Biotechs from China

Time & Date:

January 14, 2026, 16:30 – 17:15 PST

Location:

Pacific Hall, Convene, 40 O’Farrell St, San Francisco

Description:

China is emerging as a hub of global biotech innovation. Leveraging on strong capability in early discovery
and clinical resources, China’s biotech companies are joining the global innovation in the next wave of oncology and
autoimmune assets. In this panel, J.P. Morgan invited CEOs with lead assets in cell therapy and other modalities and will
discuss differentiation of their assets and strategy for business developments

(Press release, AbelZeta, JAN 6, 2026, View Source [SID1234661774])

On January 6, 2026 Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, reported that the U.S. Food and Drug Administration ("FDA") issued a "Study May Proceed" letter for the Company’s study in metastatic breast cancer which was the subject of a recent investigational new drug application for (Z)-endoxifen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This letter marks an important regulatory milestone for Atossa and to potentially expand the use of (Z)-endoxifen for metastatic ER+/HER2- Breast Cancer. We believe its activity, even in tumors that have developed resistance to other endocrine therapies and in the oncogenic signaling pathway, protein kinase C beta 1 (PKCβ1), may offer a new tool in treating this disease.," said Dr. Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer. "We appreciate the FDA’s review and look forward to advancing this clinical investigation."

About (Z)-Endoxifen

(Z)-Endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms of interest. Atossa is evaluating its potential applications in oncology and rare diseases. The Company’s proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa’s (Z)-Endoxifen is not approved for any indication.

Atossa’s (Z)-Endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide.

(Press release, Atossa Therapeutics, JAN 6, 2026, View Source [SID1234661773])

On January 6, 2026 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") reported it will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, Calif. As a global leader in life sciences, Astellas will use this premier platform to highlight its key strategic focuses and the tangible progress achieved to date in support of delivering long-term impact for patients, partners, and shareholders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the conference, President and CEO Naoki Okamura will present Astellas’ key growth drivers and commitment to disciplined execution. Chief Research & Development Officer Tadaaki Taniguchi will also join the session, and together, they will emphasize how Astellas is advancing transformative scientific breakthroughs for diseases with high unmet medical need and reinforcing its leadership in healthcare innovation and shaping the future of patient care.

Naoki Okamura, President and CEO, Astellas
"Our focus is clear: we are working to turn innovative science into meaningful VALUE for patients and drive sustainable growth. The J.P. Morgan Healthcare Conference provides an exceptional opportunity to engage with the global investment and healthcare community and demonstrate how our strategy and execution position Astellas for long-term success."

Presentation Details

Event: 44th Annual J.P. Morgan Healthcare Conference
Date & Time: January 12, 2026, at 3:00 p.m. PT
Location: Westin St. Francis, San Francisco
The presentation materials and a live webcast link will be available on the Investor Relations page of Astellas.com on the day of the presentation. A link to the on-demand replay will be made available shortly after the presentation.

As a distinguished sponsor of Biotech Showcase held in San Francisco the same week, Astellas is furthering its visibility in the global life sciences community. Chief Strategy Officer Adam Pearson will join a plenary session on partnering trends that are advancing emerging technologies and drug development innovation—underscoring Astellas’ commitment to pioneering science and fostering collaborations to benefit patients worldwide.

(Press release, Astellas Pharma, JAN 6, 2026, View Source [SID1234661772])

On January 6, 2026 Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, reported that Jin-Seok Seo, Chief Executive Officer and Hyuk-Jae Lee, Senior Executive Vice President at Celltrion, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California on January 12–15, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Celltrion’s presentation and fireside chat are scheduled for Tuesday, January 13, 2026, from 3:45 PM to 4:25 PM (PT) at the Grand Ballroom, The Westin St. Francis San Francisco Union Square.

(Press release, Celltrion, JAN 6, 2026, View Source [SID1234661771])

On January 6, 2026 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), reported that the Company will participate in the American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium 2026 taking place January 8-10, 2026, in San Francisco, California. Details of the posters are included below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First Poster Details:
Abstract Title: BXQ-350 efficacy and safety evaluation in first line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 plus bevacizumab in newly diagnosed metastatic colorectal carcinoma.
Abstract Number: 242
Poster Board Number: K2
Session Title: Poster Session C: Cancers of the Colon, Rectum, and Anus
Session Date: Saturday, January 10, 2026
Session Time: 7:00-7:55 AM
Presenter: Dr. Reema Patel

Second Poster Details:
Abstract Title: A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma.
Abstract Number: TPS273
Poster Board Number: L7
Session Title: Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Session Date: Saturday, January 10, 2026
Session Time: 7:00-7:55 AM
Presenter: Dr. Tariq Arshad

Third Poster Details:
Abstract Title: Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.
Abstract Number: 105
Poster Board Number: D17
Session Title: Poster Session C: Cancers of the Colon, Rectum, and Anus
Session Date: Saturday, January 10, 2026
Session Time: 7:00-7:55 AM
Presenter: Michael Gazda, Ph.D.
The abstracts are scheduled to be posted to the ASCO (Free ASCO Whitepaper) GI Online Program at 5 PM ET on Monday, January 6.

About BXQ-350
Bexion’s lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional sphingolipid activator protein, Saposin C, and a phospholipid. Multiple Phase 1 clinical trials in adult and pediatric patients have demonstrated a robust safety profile for BXQ-350 with evidence of single agent activity across multiple solid tumor types. Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in chemotherapy-induced peripheral neuropathy, an area of high unmet medical need in patients treated with oxaliplatin and other chemotoxic agents.

(Press release, Bexion, JAN 6, 2026, View Source [SID1234661770])